Catalyst Pharmaceuticals: High-Growth Specialist for Rare Diseases
Reading Time: 4 minutes
Successful with Orphan Drugs: Catalyst excels with high-margin niche products like FIRDAPSE and the growth driver AGAMREE. Strong quarter, hesitant consensus: With $0.70 per share, Catalyst clearly exceeded expectations – but analyst estimates remain conservative so far. Catalyst Pharmaceuticals is a specialized biopharmaceutical provider focused on marketing therapies for rare neuromuscular and neurological diseases. Since its establishment in 2002, the company has pursued a consistent niche strategy in the field of orphan...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
